204 related articles for article (PubMed ID: 16978022)
1. Insights into the o-acetylation reaction of hydroxylated heterocyclic amines by human arylamine N-acetyltransferases: a computational study.
Lau EY; Felton JS; Lightstone FC
Chem Res Toxicol; 2006 Sep; 19(9):1182-90. PubMed ID: 16978022
[TBL] [Abstract][Full Text] [Related]
2. Probing the mechanism of hamster arylamine N-acetyltransferase 2 acetylation by active site modification, site-directed mutagenesis, and pre-steady state and steady state kinetic studies.
Wang H; Vath GM; Gleason KJ; Hanna PE; Wagner CR
Biochemistry; 2004 Jun; 43(25):8234-46. PubMed ID: 15209520
[TBL] [Abstract][Full Text] [Related]
3. Arylamine N-acetyltransferases: characterization of the substrate specificities and molecular interactions of environmental arylamines with human NAT1 and NAT2.
Liu L; Von Vett A; Zhang N; Walters KJ; Wagner CR; Hanna PE
Chem Res Toxicol; 2007 Sep; 20(9):1300-8. PubMed ID: 17672512
[TBL] [Abstract][Full Text] [Related]
4. Identification of amino acids imparting acceptor substrate selectivity to human arylamine acetyltransferases NAT1 and NAT2.
Goodfellow GH; Dupret JM; Grant DM
Biochem J; 2000 May; 348 Pt 1(Pt 1):159-66. PubMed ID: 10794727
[TBL] [Abstract][Full Text] [Related]
5. Metabolic activation of heterocyclic aromatic amines catalyzed by human arylamine N-acetyltransferase isozymes (NAT1 and NAT2) expressed in Salmonella typhimurium.
Wild D; Feser W; Michel S; Lord HL; Josephy PD
Carcinogenesis; 1995 Mar; 16(3):643-8. PubMed ID: 7697826
[TBL] [Abstract][Full Text] [Related]
6. Metabolic activation of aromatic and heterocyclic N-hydroxyarylamines by wild-type and mutant recombinant human NAT1 and NAT2 acetyltransferases.
Hein DW; Rustan TD; Ferguson RJ; Doll MA; Gray K
Arch Toxicol; 1994; 68(2):129-33. PubMed ID: 8179482
[TBL] [Abstract][Full Text] [Related]
7. Human acetyl CoA:arylamine N-acetyltransferase variants generated by random mutagenesis.
Summerscales JE; Josephy PD
Mol Pharmacol; 2004 Jan; 65(1):220-6. PubMed ID: 14722254
[TBL] [Abstract][Full Text] [Related]
8. 3D model of human arylamine N-acetyltransferase 2: structural basis of the slow acetylator phenotype of the R64Q variant and analysis of the active-site loop.
Rodrigues-Lima F; Dupret JM
Biochem Biophys Res Commun; 2002 Feb; 291(1):116-23. PubMed ID: 11829470
[TBL] [Abstract][Full Text] [Related]
9. Description of a novel polymorphic gene encoding for arylamine N-acetyltransferase in the rhesus macaque (Macaca mulatta), a model animal for endometriosis.
Fakis G; Boukouvala S; Kawamura A; Kennedy S
Pharmacogenet Genomics; 2007 Mar; 17(3):181-8. PubMed ID: 17460546
[TBL] [Abstract][Full Text] [Related]
10. Arylamine N-acetyltransferase aggregation and constitutive ubiquitylation.
Liu F; Zhang N; Zhou X; Hanna PE; Wagner CR; Koepp DM; Walters KJ
J Mol Biol; 2006 Aug; 361(3):482-92. PubMed ID: 16857211
[TBL] [Abstract][Full Text] [Related]
11. Catalytic mechanism of hamster arylamine N-acetyltransferase 2.
Wang H; Liu L; Hanna PE; Wagner CR
Biochemistry; 2005 Aug; 44(33):11295-306. PubMed ID: 16101314
[TBL] [Abstract][Full Text] [Related]
12. The structure of arylamine N-acetyltransferase from Mycobacterium smegmatis--an enzyme which inactivates the anti-tubercular drug, isoniazid.
Sandy J; Mushtaq A; Kawamura A; Sinclair J; Sim E; Noble M
J Mol Biol; 2002 May; 318(4):1071-83. PubMed ID: 12054803
[TBL] [Abstract][Full Text] [Related]
13. Divergence of cofactor recognition across evolution: coenzyme A binding in a prokaryotic arylamine N-acetyltransferase.
Fullam E; Westwood IM; Anderton MC; Lowe ED; Sim E; Noble ME
J Mol Biol; 2008 Jan; 375(1):178-91. PubMed ID: 18005984
[TBL] [Abstract][Full Text] [Related]
14. NMR-based model reveals the structural determinants of mammalian arylamine N-acetyltransferase substrate specificity.
Zhang N; Liu L; Liu F; Wagner CR; Hanna PE; Walters KJ
J Mol Biol; 2006 Oct; 363(1):188-200. PubMed ID: 16959263
[TBL] [Abstract][Full Text] [Related]
15. Insight into the structure of Mesorhizobium loti arylamine N-acetyltransferase 2 (MLNAT2): a biochemical and computational study.
Dairou J; Flatters D; Chaffotte AF; Pluvinage B; Sim E; Dupret JM; Rodrigues-Lima F
FEBS Lett; 2006 Mar; 580(7):1780-8. PubMed ID: 16513121
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of cytochrome P450 1A2-mediated formation of N-hydroxy arylamines and heterocyclic amines and their reaction with guanyl residues.
Guengerich FP; Humphreys WG; Yun CH; Hammons GJ; Kadlubar FF; Seto Y; Okazaki O; Martin MV
Princess Takamatsu Symp; 1995; 23():78-84. PubMed ID: 8844798
[TBL] [Abstract][Full Text] [Related]
17. Arylamine N-acetyltransferases.
Sim E; Westwood I; Fullam E
Expert Opin Drug Metab Toxicol; 2007 Apr; 3(2):169-84. PubMed ID: 17428149
[TBL] [Abstract][Full Text] [Related]
18. Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens.
Hein DW; Fretland AJ; Doll MA
Int J Cancer; 2006 Sep; 119(5):1208-11. PubMed ID: 16570281
[TBL] [Abstract][Full Text] [Related]
19. Purification and biochemical characterization of hepatic arylamine N-acetyltransferase from rapid and slow acetylator mice: identity with arylhydroxamic acid N,O-acyltransferase and N-hydroxyarylamine O-acetyltransferase.
Mattano SS; Land S; King CM; Weber WW
Mol Pharmacol; 1989 May; 35(5):599-609. PubMed ID: 2725469
[TBL] [Abstract][Full Text] [Related]
20. Arylamine N-acetyltransferase activity of the human placenta.
Derewlany LO; Knie B; Koren G
J Pharmacol Exp Ther; 1994 May; 269(2):756-60. PubMed ID: 8182542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
